Physician profile
David Vu
NPI 1851367999
$2,076.90
in general payments reported to CMS, 2019-2025
27 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $443 · 2021: $406 · 2022: $279 · 2023: $126 · 2024: $247 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $592.06 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.84 | 2020-2024 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $206.81 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $154.71 | 2020-2025 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $97.20 | 2019-2023 | |
| Glaxosmithkline, LLC. | $75.17 | 2019-2024 | Trelegy Ellipta |
| Abbott Laboratories | $72.17 | 2019-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $69.12 | 2021-2022 | |
| Amarin Pharma, INC. | $64.14 | 2019-2021 | |
| Tepha INC | $58.77 | 2020 | |
| Lilly USA, LLC | $56.02 | 2019-2025 | Zepbound, Mounjaro |
| Pulmonx Corporation | $53.59 | 2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Sunovion Pharmaceuticals INC. | $50.16 | 2021-2022 | |
| Mylan Specialty L.P. | $45.82 | 2024 | Yupelri |
| Sumitomo Pharma America, INC. | $25.63 | 2024 | Gemtesa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $22.84 | 2020 | |
| Pfizer INC. | $20.44 | 2020 | |
| Virtus Pharmaceuticals LLC | $19.43 | 2021 | |
| Amgen INC. | $17.92 | 2025 | Repatha, Otezla |
| Recor Medical INC | $17.43 | 2024 | Paradise Renal Denervation System |
| Allergan, INC. | $16.78 | 2019 | |
| Eisai INC. | $16.50 | 2020 | |
| Esperion Therapeutics, INC. | $15.22 | 2020 | |
| Dexcom, INC. | $14.88 | 2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $14.68 | 2024 | Voquezna |
| Viatris Specialty LLC | $14.41 | 2025 | Yupelri |
| Forte Bio-Pharma LLC | $4.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.